Price
152.97
-2.2%52W Range
Market Cap
₹1,206.07 Cr
Traded: ₹6.29 Cr (0.52%) 0.0x
Free Float: ₹258.46 Cr (2.43% of FF traded)
Volume · 60D trend
4.1 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | -- | +16.0% | -- | -- | -- |
| Sales | -- | -- | -- | -- | +104.0% | -- |
| Profit | -- | -- | +1058.0% | -- | +65.0% | Decelerating |
| Return | -- | -- | -- | -- | -- | -- |
Quarterly Results
Jun 2025
Mar 2025
Dec 2024
Sep 2024
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 34 | 31 | 23 | 13 | 15 | 10 | 12 | 9 |
| Expenses | 26 | 24 | 16 | 8 | 7 | 7 | 7 | 5 |
| Operating Profit | 8 | 6 | 7 | 5 | 9 | 3 | 5 | 5 |
| OPM % | 24.4% | 20.6% | 29.7% | 39.6% | 56.5% | 26.7% | 39.0% | 51.6% |
| Other Income | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 7 | 5 | 5 | 4 | 7 | 2 | 4 | 4 |
| Tax % | 23.6% | -3.0% | 26.4% | 28.5% | 27.8% | 16.9% | 29.7% | 26.3% |
| Net Profit | 5 | 5 | 4 | 3 | 5 | 1 | 3 | 3 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 0.7 | 0.6 | 0.4 | 0.5 | 0.8 | 0.2 | 15.5 | 18.4 |
| Sales Growth (YoY) | -- | 213.0% | 97.0% | 37.0% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -- | 31.5% | 79.8% | -15.3% | 56.0% | -17.1% | 25.3% | -- |
| OP Growth (YoY) | -2.9% | 141.4% | 50.0% | 5.3% | -- | -- | -- | -- |
| OP Growth (QoQ) | 32.9% | -8.7% | 34.8% | -40.6% | 230.3% | -43.3% | -5.3% | -- |
| Profit Growth (YoY) | 7.0% | 293.8% | 17.6% | -9.8% | -- | -- | -- | -- |
| EPS Growth (YoY) | -- | 178.3% | -97.6% | -97.4% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 73.0% | -21.3% | -44.7% | 269.6% | -98.5% | -15.6% | -- |
| OP Margin | -- | 20.6% | 29.7% | 39.6% | 56.5% | 26.7% | 39.0% | 51.6% |
| Net Margin | -- | 15.8% | 15.9% | 22.3% | 35.4% | 13.7% | 21.5% | 31.5% |
| Material Cost % | -- | 11.0% | 13.1% | 10.1% | 9.1% | 16.1% | 8.7% | 8.8% |
| Employee Cost % | -- | 17.5% | 17.1% | 17.3% | 13.6% | 20.4% | 25.0% | 18.4% |
| P/S | 11.94 | 13.11 | -- | -- | -- | -- | -- | -- |
| P/E | 71.48 | 58.55 | -- | -- | -- | -- | -- | -- |
| P/B | 4.77 | 4.25 | 41.33 | -- | -- | -- | -- | -- |
Exchange Filings
50Statement of Deviation & Variation as on June 30, 2026
Monitoring Agency Report June 2026
Financial Results for Quarter ended June 2026
Change in Category of Mr Paresh Dhoti from Additional Director - Non Executive- Non Independent to Additional Director- Non Executive-Independent (appointment shall be subject to approval ....
Outcome of Board meeting for consideration of Unaudited financial results and other matters.
Gujarat Kidney And Super Speciality Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Unaudited ....
Newspaper publication of Notice of Postal Ballot
Compliance Certificate under Reg 74 (5) of SEBI (Depositories and Participants) Regulations, 2018
Appointment of Mr (Dr) Paresh Dhoti as Additional Non Executive Independent Director
Acquisition of 51% Stake in Blue Tree Clinics LLC
Outcome of Postal Ballot
Scrutinizer''s Report for Postal ballot concluded on 04.07.2026.
Intimation of closure of Trading Window
Notice of Postal ballot
Annual Secretarial Compliance Report for the year ended on March 31, 2026
Submission of Newspaper publication of Audited Standalone and Consolidated Financial Results for quarter and year ended on 31.03.2026
Appointment of Internal Auditor
Announcement of Quarterly and Annual Results for the Financial year ended on 31.03.2026
Financial results as on 31.03.2026
Appointment of Secretarial Auditor
Gujarat Kidney And Super Speciality Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve 1) Audited ....
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
Monitoring Agency Report for the Quarter ended on 31.03.2026
GKSL Scales Up Renal Care : 100 units AI Powered Haemodialysis Machines to be inducted across network. First 8 Machines to go live at Gujarat Multi Speciality Hospital GOdhra, GUjarat within ....
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Approval of Incorporation of Wholly Owned Subsidiary (WOS)
Appointment of Mrs Vishakha Mahesh Phadke as Company Secretary and Compliance Officer
Outcome of Postal Ballot
Postal Ballot Scrutinizer''s Report
Intimation about payment of fine levied under Regulation 29 of SEBI (LODR), Regulations 2015.
Intimation of receipt of Notice for Non compliance with Regulation 29 (2)/ 29 (3) of SEBI (LODR) Regulations, 2015
Certificate under reg 74(5) of SEBI (DP) Regulation 2011
Intimating completion of dispatch of Notice of Postal ballot
Intimation of closure of Trading Window
Notice of Postal Ballot and e-voting
The company executed Parekhs Hospital Private Limited as Wholly Own Subsidiary of Gujarat Kidney and super speciality Limited on 22nd March 2026
Intimation under regulation 30 of LODR, The company paid penalty imposed by BSE and NSE.
In reference to the captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held on today, i.e., Thursday, March 19, 2026, at the Registered ....
Appointment of Internal Auditor
Appointment of Secretarial Auditor
We hereby submit disclosure regarding the fine imposed by National Stock Exchange of India Limited and BSE Limited for non-submission of unaudited financial result of quarter and half yearly ....
Disclosure of delay for Unaudited financial result for the second quarter ended on September 30,2025. The company listed on 30th December 2025, so we uploaded financial result of 31st ....
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulation 2015, We wish to inform you that Mrs. Niki Paresh Tiwari, Company Secretary and Compliance ....
Newspaper advertisement for unaudited standalone and consolidated financial result for the quarter and nine months ended on December 31,2025.
Pursuant to Regulations 30 and 33 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), ....
Outcome of Board meeting held on 14th February 2026 for the approval of unaudited financial result standalone and consolidated of the company for quarter and nine months ended December ....
Intimation under Regulation 30 under LODR regulation 2015, we would like to inform you that, we received order from NCLT Ahmedabad under section 131 of the Companies Act 2013.
Statement of deviation and variation for 31 december 2025
Please find monitoring agency report for 31 December 2025
Gujarat Kidney And Super Speciality Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve and take ....
Held by ETFs
1 ETFs hold gksl · sorted by weight
Held by Mutual Funds
1 schemes hold gksl · sorted by weight